Related Experiment Video
Updated: Aug 4, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation
J P Shannon1, M V Silva, D C Brown
1Department of Pathology, University of New Mexico Health Science Center, Albuquerque, USA.
Insights
Researchers developed a novel peptide, IP01, that inhibits ICAM-1-mediated cell adhesion, crucial for inflammatory responses. This small molecule offers potential for studying ICAM-1/LFA-1 interactions and developing new therapeutics.
Area of Science:
- Immunology
- Biochemistry
- Drug Discovery
Background:
- Leukocyte adherence via ICAM-1/LFA-1 binding is vital for immune and inflammatory functions.
- Inhibiting ICAM-1/LFA-1 interactions shows therapeutic potential in lymphoma and inflammatory diseases like arthritis and septic shock.
Purpose of the Study:
- To develop and characterize a small peptide antagonist targeting ICAM-1-dependent cell aggregation.
- To identify a novel molecule for studying ICAM-1 biology and developing therapeutics.
Main Methods:
- Utilized phage display technology with a cyclic nonapeptide library to select for ICAM-1 binding peptides.
- Synthesized and tested cyclic and linear IP01 peptides for their ability to inhibit ICAM-1-mediated cell aggregation.
- Performed alanine scanning mutagenesis to identify key amino acids in IP01 responsible for inhibition.
- Assessed IP01's effect on neutrophil adhesion under physiologic flow conditions.
Main Results:
- Identified and selected the cyclic nonapeptide IP01 (C*LLRMRSIC*) for its potent inhibition of ICAM-1-dependent cell aggregation.
- Cyclic and linear IP01 peptides inhibited ICAM-1-mediated aggregation at 1 mM, with cyclic IP01 showing an IC50 of ~970 µM.
- IP01 did not affect aggregation mediated by ICAM-2 or ICAM-3, indicating specificity.
- Key inhibitory residues in cyclic IP01 were identified as leucine 2, leucine 3, methionine 5, and arginine 6.
- Cyclic IP01 effectively inhibited neutrophil firm adhesion to endothelium in a flow assay.
Conclusions:
- A novel small peptide, cyclic IP01, was developed that specifically inhibits ICAM-1-dependent cell adhesion.
- IP01's mechanism of action is distinct from LFA-1, offering a unique therapeutic target.
- IP01 serves as a valuable tool for investigating ICAM-1/LFA-1 biology and as a lead for small molecule drug development.
Abstract:
Leukocyte adherence mediated by intercellular adhesion molecule-1 (ICAM-1) binding to leukocyte function-associated antigen (LFA-1) is required for proper inflammatory and immune function. Inhibition of ICAM-1\LFA-1 binding using monoclonal antibodies (mAb) has been shown to be efficacious at inhibiting lymphoma metastasis as well as leukocyte emigration into tissue in a number of inflammatory diseases such as ischemia-reperfusion injury, septic shock and rheumatoid arthritis. In this report, we describe the development and characterization of a small peptide antagonist of ICAM-1-dependent cell aggregation. By using repeated selection of a cyclic nonapeptide phage display library on purified ICAM-1, we identified phage that were competitively eluted with anti-ICAM-1 mAb. The peptide sequences were determined by nucleotide sequencing, and the peptide sequence (C*LLRMRSIC*) (IP01) that occurred most frequently was chosen for further study. Phage expressing this peptide sequence specifically bound ICAM-1 over a range of 5 x 10(6) to 1 x 10(8) phage/microL. A cyclic IP01 peptide, linear IP01 peptide, a cyclic nonapeptide with a scrambled IP01 sequence, and a random, cyclic nonapeptide were synthesized. The cyclic and linear IP01 peptides were able to inhibit ICAM-1-mediated cell aggregation at a concentration of 1 mM, whereas the random and scrambled peptide sequences did not alter aggregation. Cyclic IP01 had a half-maximal inhibitory concentration of approximately 970 microM. Cyclic IP01 did not inhibit cellular aggregation that was dependent on ICAM-2 or ICAM-3. Alanine substitutions in the cyclic IP01 identified at least four amino acids necessary for inhibition of ICAM-1 dependent cell aggregation; leucine 2, leucine 3, methionine 5, and arginine 6. Finally, we showed that cyclic IP01 can inhibit firm adhesion of neutrophils to endothelium, a critical event in inflammatory diseases, in an assay that recapitulates physiologic flow conditions. Homology of IP01 with the primary amino acid sequences of the alpha or beta subunit of LFA-1 was not identified. Thus, we identified a unique molecule that inhibits ICAM-1 dependent cell adhesion, but is not related to the primary sequence of the ICAM-1 ligand LFA-1. Due to the small size and ability to block cell-cell adhesion, IP01 may serve as a useful tool for study of ICAM-1 and LFA-1 biology as well as for the development of small molecule therapeutics.
Related Concept Videos
Overview of Cell-Matrix Interactions
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions
Some...
Adherens Junctions
Adherens Junctions are Dynamic
The endothelial cells...
Cell Adhesion Molecules - Types and Functions
CAM Families
The Integrin family of proteins is primarily involved in a...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

